Navigation Links
Thera Max™ Cold and Flu Debuts in Times Square During the Height of the 2011 / 2012 Holiday Season
Date:12/13/2011

NEW YORK, Dec. 13, 2011 /PRNewswire/ -- TheraBiogen, Inc. (OTC BB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today that the Company's Thera Max™ Cold and Flu product will be prominently displayed on a billboard ad in Times Square at 42nd Street between 7th and 8th Avenues as part of the Company's ongoing product marketing program.

The Thera Max™ ad will run from December 15, 2011 through January 15, 2012 and will be seen by millions of people traveling through Times Square this holiday season.

Kelly Hickel, CEO of TheraBiogen, commented, "Our Times Square billboard provides significant exposure for the Thera Max™ brand through New Year's Eve and into 2012 as we continue to seek timely marketing opportunities to benefit our customers and ultimately our shareholders."

Thera Max™ Cold and Flu is an all-natural, non-zinc, non-addictive, over-the-counter cold flu relief agent.  Over 50 million Americans contract the flu each year and consumer demand for a homeopathic, non-zinc remedy is a 2.5 billion dollar market.

Thera Max™ is available for purchase in over twelve thousand locations including Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts, Big Y Supermarkets and other major retailers.  For more information on Thera Max™ visit our website at www.theramaxrelief.com, our  Facebook page at facebook.com/theramaxnasalspray or follow us on Twitter at http://twitter.com/TheraMaxRelief.

About TheraBiogen, Inc.TheraBiogen is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.

 Company Contact:Public Relations Contact:Investor Contact:TheraBiogen, Inc.

Megan Megale

Boutcher & BoutcherKelly T. Hickel, CEO

Megale Public Relations

Aimee Boutcher732-294-8705

703-625-8093

973-239-2878kthickel@therabiogen.com

mmegale@megalepr.com

  


'/>"/>

SOURCE TheraBiogen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
2. ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease
3. UKs National Health System Rejects Drug Therapy for Diabetic Macular Edema
4. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients With Minimal Impact on Existing Cytopenias Providing Important Therapeutic Niche In Treatment of MF
5. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
6. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
7. Genetic and Proteomic Advances Pave the Way for Next-Generation Leukemia Therapies
8. Elektas Leksell Gamma Knife Perfexion Earns Nearly Perfect Score in 2011 KLAS Radiation Therapy Report
9. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
10. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
11. Future Therapeutic Drug Monitoring Market: US, Europe, Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):